Novartis and Pfizer are among the companies best positioned to take advantage of future precision and personalised medicine disruption in the pharmaceuticals industry, our analysis shows.

The assessment comes from GlobalData’s Thematic Research ecosystem, which ranks companies on a scale of 1 to 5 based on their likelihood to tackle challenges like precision and personalised medicine and emerge as long-term winners of the pharmaceuticals sector.

According to our analysis, Novartis, Pfizer, Catalent, Johnson & Johnson, Roche, AstraZeneca, Sanofi, Bristol Myers Squibb, Amgen, Gilead Sciences, Patheon, Lonza, Takeda Pharmaceutical, Merck, Eli Lilly, IQVIA, AbbVie and Parexel are the companies best positioned to benefit from investments in precision and personalised medicine, all of them recording scores of 5 out of 5 in GlobalData’s Drug Development Thematic Scorecard.

The final column in the table represents the overall score given to that company when it comes to their current precision and personalised medicine position relative to their peers. A score of five indicates that a company is a dominant player in this space, while companies that score less than three are vulnerable to being left behind.

This article is based on GlobalData research figures as of 21 January 2022. For more up-to-date figures, check the GlobalData website.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.